Neurogene (NASDAQ:NGNE) Trading 5.2% Higher – Here’s What Happened

Posted by Brian Himes on Sep 1st, 2026

Neurogene Inc. (NASDAQ:NGNE – Get Free Report) shares shot up 5.2% during mid-day trading on Tuesday . The stock traded as high as $38.21 and last traded at $38.13. Approximately 91,933 shares changed hands during trading, a decline of 51% from the average daily volume of 188,166 shares. The stock had previously closed at $36.24.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NGNE. Canaccord Genuity Group decreased their price objective on shares of Neurogene from $180.00 to $166.00 and set a “buy” rating for the company in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a research report on Friday, July 17th. HC Wainwright decreased their target price on shares of Neurogene from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, August 12th. UBS Group set a $70.00 price target on Neurogene in a report on Wednesday, June 3rd. Finally, Rodman & Renshaw began coverage on Neurogene in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $70.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $83.67.

Check Out Our Latest Report on NGNE

Neurogene Stock Up 4.5%

The business’s fifty day moving average is $35.89 and its 200-day moving average is $28.51. The company has a market cap of $757.78 million, a PE ratio of -7.53 and a beta of 1.70.

Neurogene (NASDAQ:NGNE – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($1.53) earnings per share for the quarter, missing the consensus estimate of ($1.42) by ($0.11). Analysts forecast that Neurogene Inc. will post -5.62 EPS for the current fiscal year.

Insider Transactions at Neurogene

In other Neurogene news, CFO Christine Mikail Cvijic sold 4,200 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $36.13, for a total transaction of $151,746.00. Following the completion of the sale, the chief financial officer owned 84,040 shares of the company’s stock, valued at approximately $3,036,365.20. The trade was a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 9,600 shares of company stock worth $339,932 over the last three months. Insiders own 11.68% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in NGNE. BlackRock Inc. bought a new position in shares of Neurogene during the 2nd quarter valued at approximately $33,274,000. Trails Edge Capital Partners LP purchased a new position in Neurogene during the second quarter valued at approximately $22,483,133. Balyasny Asset Management L.P. purchased a new position in Neurogene during the third quarter valued at approximately $12,114,000. Logos Global Management LP bought a new position in shares of Neurogene in the fourth quarter worth approximately $4,017,000. Finally, Moore Capital Management LP bought a new position in shares of Neurogene in the second quarter worth approximately $4,454,000. Institutional investors own 52.37% of the company’s stock.

About Neurogene

(Get Free Report)

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.